American Century Companies Inc. Purchases 50,238 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

American Century Companies Inc. grew its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 55.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 141,265 shares of the biopharmaceutical company's stock after buying an additional 50,238 shares during the period. American Century Companies Inc. owned 0.08% of ACADIA Pharmaceuticals worth $2,592,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its stake in ACADIA Pharmaceuticals by 380.3% during the 4th quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock worth $45,576,000 after acquiring an additional 1,966,607 shares in the last quarter. Great Lakes Advisors LLC acquired a new position in ACADIA Pharmaceuticals in the fourth quarter valued at approximately $9,909,000. Burney Co. purchased a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter worth approximately $6,953,000. State Street Corp boosted its stake in ACADIA Pharmaceuticals by 3.0% in the third quarter. State Street Corp now owns 5,973,874 shares of the biopharmaceutical company's stock valued at $91,878,000 after acquiring an additional 173,084 shares in the last quarter. Finally, Barclays PLC grew its stake in ACADIA Pharmaceuticals by 126.2% during the 3rd quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company's stock worth $4,269,000 after buying an additional 154,854 shares during the last quarter. Hedge funds and other institutional investors own 96.71% of the company's stock.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 2,708 shares of the stock in a transaction on Tuesday, April 8th. The shares were sold at an average price of $14.82, for a total transaction of $40,132.56. Following the sale, the executive vice president now directly owns 59,456 shares of the company's stock, valued at approximately $881,137.92. This represents a 4.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the sale, the director now directly owns 17,595 shares in the company, valued at $320,756.85. This represents a 21.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,169 shares of company stock worth $242,686 in the last 90 days. 28.30% of the stock is owned by company insiders.

ACADIA Pharmaceuticals Trading Up 3.3 %

NASDAQ:ACAD traded up $0.47 during mid-day trading on Friday, hitting $14.58. The company had a trading volume of 1,904,307 shares, compared to its average volume of 1,854,084. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of 18.69 and a beta of 0.54. ACADIA Pharmaceuticals Inc. has a 1 year low of $13.40 and a 1 year high of $20.68. The business has a fifty day simple moving average of $17.57 and a 200-day simple moving average of $16.96.

Analyst Upgrades and Downgrades

A number of research firms have commented on ACAD. Guggenheim lowered shares of ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $23.00 to $20.00 in a research note on Friday, January 3rd. Deutsche Bank Aktiengesellschaft started coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They set a "hold" rating and a $22.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Cantor Fitzgerald restated an "overweight" rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Finally, Needham & Company LLC restated a "buy" rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Tuesday. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $23.93.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.